Simvastatin Alleviates Intestinal Ischemia/Reperfusion Injury by Modulating Omi/HtrA2 Signaling Pathways

PurposeThe objective of this research was to survey the therapeutic action of simvastatin (Sim) on intestinal ischemia/reperfusion injury (II/RI) by modulating Omi/HtrA2 signaling pathways.MethodsSprague Dawley rats were pretreated with 40 mg/kg Sim and then subjected to 1 hour of ischemia and 3 hours of reperfusion. The blood and intestinal tissues were collected, pathologic injury was observed, the contents of serum tumor necrosis factor-α and interleukin–6 (IL–6) were estimated, and superoxide dismutase, methane dicarboxylic aldehyde, and cysteinyl aspartate specific proteinase–3 (caspase–3) levels, as well as the expressions of Omi/HtrA2 and caspase–3, were measured in the intestinal tissues.ResultsSim preconditioning mitigated the damnification of intestinal tissues by decreasing oxidative stress, inflammatory damage, and apoptosis and downregulating the expression of Omi/HtrA2 compared to the ischemia/reperfusion group, while Sim+Ucf–101 significantly augmented this effect.ConclusionThese results suggest that Sim may alleviate intestinal ischemia/reperfusion injury by modulating Omi/HtrA2 signaling pathways.     

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC

IntroductionGut microbiome affecting the responses to immune checkpoint inhibitors against advanced NSCLC has been investigated in the Western population. However, considering pre-existing genetic and gut microbiota variation, the relevance remains unknown in the East-Asian NSCLC population. This study is designed to explore the relationship between gut microbiome and clinical outcomes in Chinese patients with NSCLC who have received treatment using an anti–programmed death 1 (PD-1) blockade.MethodsThirty-seven patients with advanced NSCLC receiving treatment with nivolumab were enrolled in CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491). Fecal samples were collected at the starting point, when patients received nivolumab, at clinical evaluation, and when disease progression was noted. 16S ribosome RNA gene sequencing was applied to assess gut microbiota profiles. Peripheral immune signatures were determined by multicolor flow cytometry in parallel.ResultsWhen subgrouping patients into responder (R) and nonresponder according to the clinical response assessed using Response Evaluation Criteria in Solid Tumor version 1.1, R patients harbored higher diversity of gut microbiome at the starting point with stable composition during the treatment. Patients with high microbiome diversity had significantly prolonged progression-free survival when compared to those with low diversity. Compositional difference was observed between the two groups as well with the enrichment of Alistipes putredinis, Bifidobacterium longum, and Prevotella copri in R whereas Ruminococcus_unclassified enriched in nonresponding patients. Analysis of systemic immune responses using multicolor flow cytometry revealed that patients with a high abundance of microbiome diversity in the gut had a greater frequency of unique memory CD8⁺ T cell and natural killer cell subsets in the periphery in response to anti–PD-1 therapy.ConclusionsOur results reveal strong correlation between gut microbiome diversity and the responses to anti–PD-1 immunotherapy in Chinese patients with advanced NSCLC. Patients with favorable gut microbiome (such as those with high diversity) exhibit enhanced memory T cell and natural killer cell signatures in the periphery. These findings provide important implications for the prediction and the evaluation of anti–PD-1 immunotherapy against NSCLC in the Chinese population.     

Chevron osteotomy versus scarf osteotomy for hallux valgus correction: A meta-analysis

BackgroundThis study intended to investigate the optimal surgical strategy in hallux valgus (HV), and to provide a basis for clinical treatment of HV.MethodsStudies related to chevron osteotomy and scarf osteotomy for HV were enrolled from online databases. Hallux valgus angle (HVA) was the main outcome variable. Enrolled studies included posttreatment data for intermetatarsal angle (IMA), American Orthopaedic Foot & Ankle Society (AOFAS) score, and complications. A random-effects model was applied for significant heterogeneity. Otherwise, a fixed-effects model was used. Heterogeneity was assessed with Q test and I² statistics. Publication bias was evaluated with Egger's test. Based on the influence of weighted mean difference values or odds ratios, a sensitivity analysis was performed.ResultsFour studies including 384 subjects were evaluated to determine the optimal surgical strategy for HV. There was no statistically significant difference between chevron and scarf groups for HVA, IMA, AOFAS score, and complication rates. Sensitivity analysis showed good stability. The likelihood of publication bias was small.ConclusionThe effects of chevron osteotomy and scarf osteotomy for HV are comparable. Chevron osteotomy is less technically demanding.     

通心络对急性脑梗死治疗作用基础与临床研究

目的通心络对急性脑梗死治疗作用的基础和临床研究。方法135例患者随机分成治疗组和对照组。治疗前后查Tin、t—PA、PAl、AⅢ、ACA、D—dinaer、tHey、Ps、Pc,并于15天、30天、90天行ESS和Barthel指数评分。结果与治疗前相比,治疗后两组患者血Till、PAl显著下降(P相似文献   

癌痛消胶囊调节小鼠荷H22移植性肝癌细胞VEGF表达的实验研究

目的 :通过观察癌痛消胶囊对小鼠荷H22 移植性肝癌细胞血管内皮细胞生长因子 (vascularendothelialgrowthfactor,VEGF)表达的调节作用 ,探讨该药抑制肿瘤的作用是否与抑制肿瘤血管生成有关。方法 :于昆明种雄性小鼠前肢右腋皮下接种0 2mlH22 肿瘤细胞悬液(浓度为1×107/ml)进行造模。利用造模动物观察瘤块重量 ,计算肿瘤生长抑制率 ,用免疫组化法检测瘤细胞中VEGF的表达程度。结果 :与阴性对照组相比 ,癌痛消胶囊组有明显的抑瘤作用(P<0 05) ,抑瘤率为36 34 % ;病理检测显示 ,造模各组VEGF阳性表达率为100% ,但程度不同 ,癌痛消胶囊组可使肿瘤组织VEGF的表达明显下调 ,与阴性对照组比较 ,差异有显著性意义(P<0 01)。结论 :癌痛消胶囊对小鼠荷H22 移植性肝癌细胞的生长有抑制作用 ,能减少血管生成调控基因VEGF的表达。     

血舒通治疗慢性肺原性心脏病并发重症心力衰竭的疗效观察

目的观察血舒通治疗慢性肺原性心脏病(简称肺心病)并发重症心力衰竭的临床疗效.方法 52例肺心病患者,随机分为地高辛联用速尿治疗组(对照组)和地高辛、速尿、血舒通联合治疗组(治疗组),疗程均为2周.结果 2周后总有效率:治疗组为92.3%、对照组为57.7%.两组疗效差异有显著性(P<0.01).结论在应用洋地黄及利尿剂的基础上加用血舒通,能明显提高肺心病重症心衰的疗效.     

血塞通的不良反应

血塞通是三七总皂苷的纯中药制剂,具有降低机体耗氧、抑制血小板聚集、抗凝、抗血栓和扩张心脑血管等药理作用,主要用于缺血性脑血管疾病、脑出血后遗症、冠心病等的治疗。     

血栓通预防恶性肿瘤介入化疗后并发下肢深静脉血栓临床观察

目的：评价血塞栓通对预防中晚期恶性肿瘤介入化疗后下肢深静脉血栓形成（Deep Vein Thrombosis,DVT）的影响。方法：80例行介入化疗患者随机分为两组,试验组采用介入化疗前后同时配合静滴血栓通,对照组单纯介入化疗。两组介入化疗后3个月按照制定的标准比较。结果：介入化疗后3个月两组下肢深静脉血栓形成比较差异有统计学意义（P〈0.05）。结论：血栓通治疗可预防介入化疗后下肢深静脉血栓形成。     

冰麝消痛膏的薄层色谱鉴别研究

[目的]制定冰麝消痛膏的薄层色谱鉴别方法。[方法]利用薄层色谱法对处方中冰片、血竭进行鉴别。[结果]供试品与对照品(药材)色谱相对应的位置上显相同颜色的斑点,阴性样品无干扰。[结论]此法可用于冰麝消痛膏的定性鉴别。